Cover Image

Management of patients undergoing CAR-T cell therapy in Germany

Introduction: Chimeric antigen receptor positive T cell (CAR-T cell) treatment became standard therapy for relapsed or refractory hematologic malignancies, such as non-Hodgkin’s lymphoma and multiple myeloma. Owing to the rapidly progressing field of CAR-T cell therapy and the lack of generally acce...

Full description

Saved in:
Bibliographic Details
Main Authors: Penack, Olaf (Author) , Dreger, Peter (Author) , Ajib, Salem (Author) , Ayuk, Francis (Author) , Baermann, Ben-Niklas (Author) , Bug, Gesine (Author) , Kriege, Oliver (Author) , Jentzsch, Madlen (Author) , Kobbe, Guido (Author) , Koenecke, Christian (Author) , Lutz, Mathias (Author) , Martin, Sonja (Author) , Schlegel, Paul-Gerhard (Author) , Schroers, Roland (Author) , von Tresckow, Bastian (Author) , Vucinic, Vladan (Author) , Subklewe, Marion (Author) , Bethge, Wolfgang (Author) , Wolff, Daniel (Author)
Format: Article (Journal)
Language:English
Published: March 2024
In: Oncology research and treatment
Year: 2024, Volume: 47, Issue: 3, Pages: 65-75
ISSN:2296-5262
DOI:10.1159/000536201
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1159/000536201
Get full text
Author Notes:Olaf Penack, Peter Dreger, Salem Ajib, Francis Ayuk, Ben-Niklas Baermann, Gesine Bug, Oliver Kriege, Madlen Jentzsch, Guido Kobbe, Christian Koenecke, Mathias Lutz, Sonja Martin, Paul-Gerhard Schlegel, Roland Schroers, Bastian von Tresckow, Vladan Vucinic, Marion Subklewe, Wolfgang Bethge, Daniel Wolff
Description
Summary:Introduction: Chimeric antigen receptor positive T cell (CAR-T cell) treatment became standard therapy for relapsed or refractory hematologic malignancies, such as non-Hodgkin’s lymphoma and multiple myeloma. Owing to the rapidly progressing field of CAR-T cell therapy and the lack of generally accepted treatment guidelines, we hypothesized significant differences between centers in the prevention, diagnosis, and management of short- and long-term complications. Methods: To capture the current CAR-T cell management among German centers to determine the medical need and specific areas for future clinical research, the DAG-HSZT (Deutsche Arbeitsgemeinschaft für Hämatopoetische Stammzelltransplantation und Zelluläre Therapie; German Working Group for Hematopoietic Stem Cell Transplantation and Cellular Therapy) performed a survey among 26 German CAR-T cell centers. Results: We received answers from 17 centers (65%). The survey documents the relevance of evidence in the CAR-T cell field with a homogeneity of practice in areas with existing clinical evidence. In contrast, in areas with no - or low quality - clinical evidence, we identified significant variety in management in between the centers: management of cytokine release syndrome, immune effector cell-related neurotoxicity syndrome, IgG substitution, autologous stem cell backups, anti-infective prophylaxis, and vaccinations. Conclusion: The results indicate the urgent need for better harmonization of supportive care in CAR-T cell therapies including clinical research to improve clinical outcome.
Item Description:Online veröffentlicht: 10. Januar 2024
Gesehen am 13.09.2024
Physical Description:Online Resource
ISSN:2296-5262
DOI:10.1159/000536201

Similar Items